The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Ublituximab + umbralisib granted FDA fast track designation for the treatment of CLL

Nov 12, 2020
Share:

Ublituximab in combination with umbralisib (U2) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

The decision follows positive data from the phase III UNITY-CLL trial comparing U2 to obinutuzumab + chlorambucil in patients with treatment-naïve and relapsed and/or refractory (R/R) chronic CLL, which met its primary endpoint in May 2020.

U2

The U2 combination regimen comprises the investigational, anti-CD20 monoclonal antibody, ublituximab, and the investigational, once-daily, oral inhibitor of PI3K-delta and CK1-epsilon, umbralisib.

  1. GlobeNewswire. TG Therapeutics announces fast track designation granted by the FDA to ublituximab in combination with umbralisib for the treatment of adult patients with chronic lymphocytic leukemia. https://www.globenewswire.com/news-release/2020/10/21/2111770/0/en/TG-Therapeutics-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Ublituximab-in-Combination-with-Umbralisib-for-the-Treatment-of-Adult-Patients-with-Chronic-Lymphocytic-Leuke.html. Published Oct 21, 2020. Accessed Nov 12, 2020.

Share: